CytoDyn will continue to create, develop, and position a class of therapeutic monoclonal antibodies to address significant unmet global medical needs in the areas of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). As CytoDyn continues to evolve, our focus will always be to develop science for the greater good of the world and our shareholders.